Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line MK-1084-based therapy in KRAS G12C-mutated advanced non-squamous NSCLC
CTR20260429Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of calderasib in Non-small cell lung cancer (NS-NSCLC), bronchial carcinoma, sponsored by Merck & Co.. Started Feb 2026; status: active.
02
Drugs
calderasib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on CTR20260429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260429.